A rare case of giant adrenocortical carcinoma: a case report
DOI:
https://doi.org/10.18203/2349-2902.isj20251188Keywords:
Adrenocortical carcinoma, Right hypochondrium pain, IncidentalomasAbstract
Adrenocortical tumors are rare, and when large, they are often referred to as incidentalomas if detected during evaluation for unrelated symptoms. These tumors may be nonfunctional or have subtle clinical presentations, posing diagnostic and management challenges. A 50-year-old male presented with a seven-day history of dull, aching pain in the right hypochondrium, associated with a sensation of fullness in the right upper abdomen. Physical examination revealed a palpable mass in the right hypochondrium. Based on clinical evaluation, mass was suspected to be an adrenocortical malignancy. Contrast-enhanced computed tomography (CECT) identified a well-circumscribed, heterogeneous mass measuring 11×9×10 cm arising from the right adrenal gland. Hormonal workup demonstrated no functional activity, and the mass was considered an incidentaloma. The patient underwent open surgical excision of the tumor. Intraoperative findings revealed a well-encapsulated mass with no invasion of surrounding structures. Histopathological evaluation confirmed an adrenocortical carcinoma (Weiss score >3). Postoperative recovery was uneventful, and follow-up imaging at six months showed no signs of recurrence or metastasis. This case highlights the importance of evaluating incidentalomas, particularly large adrenal masses, for their potential clinical significance. Timely surgical intervention and histopathological confirmation are essential for ensuring favourable outcomes in such cases.
Metrics
References
Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551-64. DOI: https://doi.org/10.1210/jc.2013-3020
Else T, Kim AC, Sabolch A. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282-326. DOI: https://doi.org/10.1210/er.2013-1029
Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol. 2015;3:45. DOI: https://doi.org/10.3389/fcell.2015.00045
Berruti A, Baudin E, Gelderblom H. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2012;23(7):131-8. DOI: https://doi.org/10.1093/annonc/mds231
Terzolo M, Angeli A, Fassnacht M. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372-80. DOI: https://doi.org/10.1056/NEJMoa063360
Fassnacht M, Terzolo M, Allolio B. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-97. DOI: https://doi.org/10.1056/NEJMoa1200966
Young WF. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-10. DOI: https://doi.org/10.1056/NEJMcp065470
Sturgeon C, Shen WT, Clark OH. Risk assessment in adrenal incidentalomas: lessons from 131 cases. J Clin Endocrinol Metab. 2005;90(7):4172-7.
Brix D, Allolio B, Fenske W. Long-term prognosis of patients with adrenal incidentalomas. Horm Metab Res. 2015;47(3):224-9.
Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8(3):163-9. DOI: https://doi.org/10.1097/00000478-198403000-00001
Mansmann G, Lau J, Balk E. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25(2):309-40. DOI: https://doi.org/10.1210/er.2002-0031
Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273-85. DOI: https://doi.org/10.1530/eje.0.1490273
Assié G, Letouze E, Fassnacht M. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46(6):607-12. DOI: https://doi.org/10.1038/ng.2953
Kebebew E, Reiff E, Duh QY. Adrenal incidentaloma: effect of hormonal functional status and biopsy on management. Ann Surg. 2006;244(4):524-30.